These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 16798912

  • 1. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
    Putta MR, Zhu F, Li Y, Bhagat L, Cong Y, Kandimalla ER, Agrawal S.
    Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
    [Abstract] [Full Text] [Related]

  • 2. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.
    Yu D, Putta MR, Bhagat L, Li Y, Zhu F, Wang D, Tang JX, Kandimalla ER, Agrawal S.
    J Med Chem; 2007 Dec 13; 50(25):6411-8. PubMed ID: 17988082
    [Abstract] [Full Text] [Related]

  • 3. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.
    Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP, Song SS, Tang JX, Sullivan T, Agrawal S.
    Proc Natl Acad Sci U S A; 2005 May 10; 102(19):6925-30. PubMed ID: 15860583
    [Abstract] [Full Text] [Related]

  • 4. Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice.
    Zhu FG, Kandimalla ER, Yu D, Tang JX, Agrawal S.
    Int Immunopharmacol; 2004 Jul 10; 4(7):851-62. PubMed ID: 15182725
    [Abstract] [Full Text] [Related]

  • 5. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, Wüllner M, Wader T, Liu M, Kritzler A, Krieg AM.
    J Leukoc Biol; 2004 Sep 10; 76(3):585-93. PubMed ID: 15218053
    [Abstract] [Full Text] [Related]

  • 6. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.
    Li Y, Kandimalla ER, Yu D, Agrawal S.
    Int Immunopharmacol; 2005 Jun 10; 5(6):981-91. PubMed ID: 15829414
    [Abstract] [Full Text] [Related]

  • 7. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9.
    Yu D, Wang D, Zhu FG, Bhagat L, Dai M, Kandimalla ER, Agrawal S.
    J Med Chem; 2009 Aug 27; 52(16):5108-14. PubMed ID: 19650625
    [Abstract] [Full Text] [Related]

  • 8. Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.
    Putta MR, Yu D, Bhagat L, Wang D, Zhu FG, Kandimalla ER.
    J Med Chem; 2010 May 13; 53(9):3730-8. PubMed ID: 20361743
    [Abstract] [Full Text] [Related]

  • 9. Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists.
    Jurk M, Kritzler A, Debelak H, Vollmer J, Krieg AM, Uhlmann E.
    ChemMedChem; 2006 Sep 13; 1(9):1007-14. PubMed ID: 16952134
    [Abstract] [Full Text] [Related]

  • 10. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.
    Yu D, Putta MR, Bhagat L, Dai M, Wang D, Trombino AF, Sullivan T, Kandimalla ER, Agrawal S.
    Antimicrob Agents Chemother; 2008 Dec 13; 52(12):4320-5. PubMed ID: 18852281
    [Abstract] [Full Text] [Related]

  • 11. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
    Sen G, Flora M, Chattopadhyay G, Klinman DM, Lees A, Mond JJ, Snapper CM.
    Cell Immunol; 2004 Dec 13; 232(1-2):64-74. PubMed ID: 15922717
    [Abstract] [Full Text] [Related]

  • 12. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif.
    Kandimalla ER, Bhagat L, Zhu FG, Yu D, Cong YP, Wang D, Tang JX, Tang JY, Knetter CF, Lien E, Agrawal S.
    Proc Natl Acad Sci U S A; 2003 Nov 25; 100(24):14303-8. PubMed ID: 14610275
    [Abstract] [Full Text] [Related]

  • 13. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.
    Wang D, Bhagat L, Yu D, Zhu FG, Tang JX, Kandimalla ER, Agrawal S.
    J Med Chem; 2009 Jan 22; 52(2):551-8. PubMed ID: 19102653
    [Abstract] [Full Text] [Related]

  • 14. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.
    Brummel R, Roberts TL, Stacey KJ, Lenert P.
    Eur J Immunol; 2006 Jul 22; 36(7):1951-62. PubMed ID: 16791898
    [Abstract] [Full Text] [Related]

  • 15. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
    Daubenberger CA.
    Curr Opin Mol Ther; 2007 Feb 22; 9(1):45-52. PubMed ID: 17330401
    [Abstract] [Full Text] [Related]

  • 16. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
    Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S.
    Int J Oncol; 2004 Apr 22; 24(4):901-8. PubMed ID: 15010828
    [Abstract] [Full Text] [Related]

  • 17. Effect of synthetic agonists of toll-like receptor 9 on canine lymphocyte proliferation and cytokine production in vitro.
    Im Hof M, Williamson L, Summerfield A, Balmer V, Dutoit V, Kandimalla ER, Yu D, Zurbriggen A, Doherr MG, Peel J, Roosje PJ.
    Vet Immunol Immunopathol; 2008 Jul 15; 124(1-2):120-31. PubMed ID: 18452997
    [Abstract] [Full Text] [Related]

  • 18. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
    Chikh G, de Jong SD, Sekirov L, Raney SG, Kazem M, Wilson KD, Cullis PR, Dutz JP, Tam YK.
    Int Immunol; 2009 Jul 15; 21(7):757-67. PubMed ID: 19502586
    [Abstract] [Full Text] [Related]

  • 19. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
    Gantner F, Hermann P, Nakashima K, Matsukawa S, Sakai K, Bacon KB.
    Eur J Immunol; 2003 Jun 15; 33(6):1576-85. PubMed ID: 12778475
    [Abstract] [Full Text] [Related]

  • 20. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A, Calcaterra C, Mènard S, Balsari A.
    J Leukoc Biol; 2007 Sep 15; 82(3):509-18. PubMed ID: 17586660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.